Idioma:

Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis

Huang, Jing ; Wang, Xinwei ; Jin, Yiyi ; Lou, Guodong ; Yu, Zhenwei

Journal of headache and pain, 2024-04, Vol.25 (1), p.62-62 [Periódico revisado por pares]

Milan: Springer Milan

Texto completo disponível

Citações Citado por

Enviar para

Título:
Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis
Autor: Huang, Jing ; Wang, Xinwei ; Jin, Yiyi ; Lou, Guodong ; Yu, Zhenwei
Assuntos: Acetaminophen ; Adolescent ; Adult ; Analgesics ; Analgesics - economics ; Analgesics - therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal - economics ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Anticonvulsants ; Antidepressants ; Caffeine ; China - epidemiology ; Drug Prescriptions - economics ; Drug Prescriptions - statistics & numerical data ; Expenditures ; Female ; Flupenthixol ; Headache ; Humans ; Inflammation ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Migraine ; Migraine Disorders - drug therapy ; Migraine Disorders - economics ; Narcotics ; Neurology ; Nonsteroidal anti-inflammatory drugs ; NSAID ; Opioid ; Opioids ; Pain Medicine ; Patients ; Practice Patterns, Physicians' - statistics & numerical data ; Practice Patterns, Physicians' - trends ; Prescribing patterns ; Prescriptions ; Retrospective Studies ; Topiramate ; Trends ; Triptan ; Tryptamines - economics ; Tryptamines - therapeutic use ; Young Adult
É parte de: Journal of headache and pain, 2024-04, Vol.25 (1), p.62-62
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Background The objective of this study was to investigate the trends and prescribing patterns of antimigraine medicines in China. Methods The prescription data of outpatients diagnosed with migraine between 2018 and 2022 were extracted from the Hospital Prescription Analysis Cooperative Project of China. The demographic characteristics of migraine patients, prescription trends, and corresponding expenditures on antimigraine medicines were analyzed. We also investigated prescribing patterns of combination therapy and medicine overuse. Results A total of 32,246 outpatients who were diagnosed with migraine at 103 hospitals were included in this study. There were no significant trend changes in total outpatient visits, migraine prescriptions, or corresponding expenditures during the study period. Of the patients who were prescribed therapeutic medicines, 70.23% received analgesics, and 26.41% received migraine-specific agents. Nonsteroidal anti-inflammatory drugs (NSAIDs; 28.03%), caffeine-containing agents (22.15%), and opioids (16.00%) were the most commonly prescribed analgesics, with corresponding cost proportions of 11.35%, 4.08%, and 19.61%, respectively. Oral triptans (26.12%) were the most commonly prescribed migraine-specific agents and accounted for 62.21% of the total therapeutic expenditures. The proportion of patients receiving analgesic prescriptions increased from 65.25% in 2018 to 75.68% in 2022, and the proportion of patients receiving concomitant triptans decreased from 29.54% in 2018 to 21.55% in 2022 (both P < 0.001 ). The most frequently prescribed preventive medication classes were calcium channel blockers (CCBs; 51.59%), followed by antidepressants (20.59%) and anticonvulsants (15.82%), which accounted for 21.90%, 34.18%, and 24.15%, respectively, of the total preventive expenditures. Flunarizine (51.41%) was the most commonly prescribed preventive drug. Flupentixol/melitracen (7.53%) was the most commonly prescribed antidepressant. The most commonly prescribed anticonvulsant was topiramate (9.33%), which increased from 6.26% to 12.75% (both P < 0.001 ). A total of 3.88% of the patients received combined therapy for acute migraine treatment, and 18.63% received combined therapy for prevention. The prescriptions for 69.21% of opioids, 38.53% of caffeine-containing agents, 26.61% of NSAIDs, 13.97% of acetaminophen, and 6.03% of triptans were considered written medicine overuse. Conclusions Migraine treatment gradually converges toward evidence-based and guideline-recommended treatment. Attention should be given to opioid prescribing, weak evidence-based antidepressant use, and medication overuse in migraine treatment.
Editor: Milan: Springer Milan
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis

Huang, Jing ; Wang, Xinwei ; Jin, Yiyi ; Lou, Guodong ; Yu, Zhenwei

Milan: Springer Milan

Buscando em bases de dados remotas. Favor aguardar.